Followers | 14 |
Posts | 1,650 |
Boards Moderated | 0 |
Alias Born | 11/01/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Curious Case of Innovus Pharmaceuticals Inc (OTCMKTS:INNV)
http://oracledispatch.com/2016/09/19/the-curious-case-of-innovus-pharmaceuticals-inc-otcmktsinnv/
Innovus Pharmaceuticals Inc (OTCMKTS:INNV) is a low-priced trading equity that has grabbed hold of the attention of traders during the stock’s recent roller coaster ride. We’ve seen massive swings here over the last couple months. The story looks amazing. But it may be too amazing, if you know what I mean. The facts we have are examined below. Our conclusion is somewhat striking, but you will need to read on.
The recent bounce of 9% upside in the past week (the Company has very suddenly introduced a brand new major product with possible access to a $11 bln market) is actually a relatively minor affair on this chart. The key move is the rally over the Summer, capped by a 200% launch in July. Fueling this action, we’ve seen a wild combination of factors, including sales growth catching fire, with recent sequential y/y quarterly revenues jumping by over 450%, and recent guidance aiming significantly beyond even that lofty level. However, we’ve also seen some red flags in the tape, with the stock diving 25% on massive volume and no news in late August. We always take note of action like that and draw a question mark on our charts.
Innovus Pharmaceuticals, Inc. (OTCMKTS: INNV), a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States.
The company’s products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality.
INNV also has a number of product lines gestating in the pipeline, including FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health.
In response to the company’s recent surge in topline growth, INNV investors have been rewarded by upgrades to future outlooks by both SeeThruEquity and Zack’s research. Price targets now reach as high as $1/share and above.
In step with this shift in sentiment, INNV’s shares have been locked in a powerful upward trend since May of this year, advancing as much as 400% at one point, before diving 50% in August.
With revenue growth surging even faster than the stock’s share price advance, it’s no wonder analysts have become so enthusiastic on the name. Both Analysts and investors have latched onto a compelling forward narrative for INNV that centers on potential for parallels between the market for male sexual dysfunction and that for female sexual dysfunction.
The former represents a market set for sales in excess of $3.2 billion USD by 2022, according to a recent report by Grand View Research. By comparison, the latter is distinctly underserved. INNV has positioned itself to benefit from both sides of this coin.
In the first case, the company is seeing strong growth in its Vesele product, which has been tested in a recent 72-patient, 4-month survey, and shown to provide excellent complementarity to Viagra and Cialis over four key endpoints.
In the second case, the company’s key Zestra product targets the Female Sexual Interest Arousal Dysfunction (FSI/AD) market. Research suggests this market may even exceed the Male sexual dysfunction market over time, with studies showing that between 25% and 63% of women are affected, with an average point at 43% (versus 31% for men).
This may explain INNV’s recent guidance: the company paired its Q2 earnings filing with a guidance announcement calling for $5 mln in total 2016 revenues, well above analyst estimates in the $3 mln range.
This jump in performance has also put Innovus ahead of schedule on its cash position. The company actually reported positive cash flow from operations in Q2, which is well ahead of schedule. Investors should be very happy to see this, as it allows the company to take more risk, and have more protection against unforeseen detractors over the intermediate term.
In terms of fueling further growth, the company noted on its earnings call that its Fluticare product (still in the pipeline) could generate $10-15 mln in revenues once a mature distribution footprint was in place. That would obviously be another game changer for the stock.
And that seems like a full story, right? But we didn’t even get to the recent news. At the close of August, seemingly out of nowhere, the Company announced the introduction of something called RecalMax, which is aimed as an OTC supplement for Parkinson’s disease and Alzheimer’s. While this is a huge market ($11 bln), the idea that a non-FDA approved medication is being touted as “the solution” by the Company is frankly “jumping the shark” for our tastes. And furthermore, the fact that this is not rallying the stock further is another red flag.
Earning a current market cap value of $2.2M, INNV has a decent store ($198.13k) of cash on the books, alongside total assets topping $8M, which must be weighed relative to an appreciable load ($945.35k) of total accumulated debt. Superficially, there’s a lot here that looks a bit too good to be true. Perhaps it is all true. We will reserve judgment for now and head back to the due diligence watch. If we start to get the feeling that the INNV story is as good as it looks, you will know about it here first.
The first harvest was a month ago. I think this will temporarily drop some if we don't get approval soon or if we are not approved.
Well as a penny stock all prs are paid for but this has significant news in it.
I'll continue holding
I disagree looking at the news that just came out today
$SPRWF glad I held on to this one and I want to add more
http://www.meetmax.com/sched/event_35153/~public/conference_companies.html?event_id=35153
a lot of people speaking, I wonder if it is recorded
More awareness even if it's not great. I'm wondering if this is a promo
Man-made diamonds: an investor’s best friend?
Synthetic diamonds are becoming well positioned to shine in the market.
https://news.markets/shares/synthetic-diamonds-investors-best-friend-25360/
Man-made diamonds are becoming increasingly identical to those that are naturally sourced. Do they have what it takes to disrupt the $80 billion global diamond industry?
Many are beginning to think so. One Las Vegas-based company, Centaurus Diamond Technologies (OTCPK:CTDT), has patented a technology that enables the high volume production of diamonds that are chemically, atomically and structurally identical to natural ones.
Apart from being a girl’s best friend, diamonds are chemically resistant and the hardest known naturally occurring material. Diamonds have great industrial capabilities for which they are widely used for cutting, polishing and grinding tools. And Centaurus’s new technology aims to bring about high-volume, cost-efficient diamond production to provide affordable, industrial-quality diamonds to companies worldwide.
The company’s shares are up 330% from this time last year. Analyst Robert Goldman from Goldman Research predicts that the company is poised to make waves in the market, rating it as a ‘speculative buy’.
Game-changing technology
It won’t be long before Centaurus enters the consumer jewelry market, and it is far from the first company to do so. Retailers are already selling synthetic diamonds that are practically indistinguishable from their natural counterparts at discounts of 30 to 40%.
And synthetic diamond retailers are attracting a great deal of attention from investors – and receiving celebrity attention from the likes of Leonardo DiCaprio.
As the synthetic diamond business grows will the man-made business be left behind?
Although it may be good news for the price-conscious, with synthetic diamonds being sold at retail for a fraction of the price of natural diamonds, will this change the way that the diamond industry prices naturally-sourced diamonds in the future.
De Beers, owned by Anglo American (LON:AAL), owns 34% of the gemstone’s market share and is adamantly against selling synthetic diamonds. “De Beers’ focus is on natural diamonds,” says Simon Lawson, head of De Beers’ UK technology division, adding that: “We would not do anything that would cannibalize that industry”.
DeBeers even has its own synthetic diamond lab that focuses on detecting the man-made diamonds that are polluting its trade. It says its method of detection, which involves a $55,000 piece of technology “underpins the integrity of natural diamonds and ensures that consumers cannot be duped into buying a synthetic diamond”.
A business opportunity or a worrying threat?
It all depends on consumer tastes. “Lab-grown diamonds are a growing threat to the diamond industry because they are of the highest quality,” says Citi Research in a report titled ‘Disruptive Technology in Mining’. It adds it’s not an immediate problem for the diamond mining industry, but could evolve into a threat in 10 or 15 years’ time.
“The hope for the miners is that consumers will continue to see such diamonds as synthetic and not proper diamonds.”
The industry could stand to benefit from man-made diamonds if retailers take the stance of offering synthetic stones as more affordable alternatives for entry level buyers who may well plan to upgrade to a naturally-sourced diamond in the future.
McKinsey & Co warns that if consumers lose faith in diamonds, either by losing faith in the natural diamond supply chain – for example, through an influx of synthetic diamonds – or if diamonds lose their emotional equity, a reputation-driven demand shock might occur.
“This could have effects similar to those in the fur industry in the 1990s, following extensive negative exposure in the media.”
nothing worth posting about at the moment?
$INNV INNOVUS PHARMA (OTCMKTS:INNV) Shorted Shares Increased By 59.91%
http://presstelegraph.com/2016/08/31/innovus-pharma-otcmktsinnv-shorted-shares-increased-by-59-91/
The stock of INNOVUS PHARMA (OTCMKTS:INNV) registered an increase of 59.91% in short interest. INNV’s total short interest was 960,400 shares in August as published by FINRA. Its up 59.91% from 600,600 shares, reported previously. With 2.67 million shares average volume, it will take short sellers 0 days to cover their INNV’s short positions. The stock decreased 4.71% or $0.014 on August 30, hitting $0.283. About 3.14M shares traded hands or 56.22% up from the average. Innovus Pharmaceuticals Inc (OTCMKTS:INNV) has risen 559.67% since January 27, 2016 and is uptrending. It has outperformed by 544.10% the S&P500.
Innovus Pharmaceuticals, Inc. is a pharmaceutical firm engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The company has a market cap of $30.08 million. The Firm markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It currently has negative earnings. It has commercial agreements in over 60 countries around the world through its commercial partners.
The information provided on this website is for individual use only and should be considered strictly informational in nature. The article is not advice, and should not be treated as such. We are in no way responsible for any investment loss or damages. All content in our articles is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our articles. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. We make no recommendation that the securities of the companies profiled or discussed in on our website should be purchased, sold or held by investors.
$INNV Catching Up With Innovus Pharmaceuticals Inc (OTCMKTS:INNV)
http://www.insiderfinancial.com/catching-up-with-innovus-pharmaceuticals-inc-otcmktsinnv/116860/
By Chris Sandburg / in Biotech & Pharma, Momentum Stocks, Stocks / on Thursday, 01 Sep 2016 02:13 AM / 0 Comment / 152 views
Innovus Pharmaceuticals Inc (OTCMKTS:INNV) has been one of our favorite picks year to date, and throughout the first half of the year, the stock recorded some solid gains for its holders. Over the last month or so, however, markets have sold off on the company somewhat, and it currently sits a little over 50% off year to date highs. The question now, is what’s next? Is the recent pull back just that – an opportunity to get in on a correction ahead of a fourth quarter recovery? Or, is Innovus going to struggle going forward?
We’re going to maintain our bias, and say the former is the more likely scenario, and here’s why.
First, a quick description of the company for our new readers. Innovus is a commercial stage healthcare company with a wide portfolio of already approved products selling across seven countries. The majority of its portfolio addresses conditions of a sexual nature – premature ejaculation, muted sexual desire, that sort of thing. It’s lead products include Zestra, a non-medicated consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation and Sensum+, a non-medicated consumer care cream that enhances penile sensitivity, among others.
During the second quarter of 2016, this product portfolio generated a little over $1 million revenues, for the company, up nearly 350% on the $244K recorded a quarter earlier. Innovus is cash flow positive, although take this with a pinch of salt as the company recorded a net loss of $4.3 million a last quarter.
The company just announced a flurry of approvals in India, which will see all three of the above mentioned products plus another, Zestra Glide, hit markets in India before the year is out. It’s got a distribution deal in place associated with these approvals, which should bring in $2.6 million in revenues annually across the next ten years.
All this is secondary at the moment, however, to a pipeline product called Fluticare; at least from a wider markets perspective. We believe markets should be valuing the company a little more favorably based on just its current portfolio, but sentiment is sentiment, so let’s look at Fluticare.
Innovus acquired the OTC rights to Fluticare as part of an acquisition of its then owner Novalere in February last year, and has since been on a mission to get an ANDA approved so it can start marketing the product commercially. It’s currently approved as a prescription, and is the number one prescribed allergy treatment ingredient for temporary relief of the symptoms of hay fever or upper respiratory allergies. If the company can gain approval for an OTC marketing push, it’s going to be entering a more than $1 billion market currently dominated by big pharma players such as GlaxoSmithKline plc (ADR) (NYSE:GSK). Yes, it will be tough to market against a company like GSK, but given the company’s current valuation and sales, it won’t take much penetration (even just a few percentage points) to completely transform Innovus’ financial position.
So when are we looking for an approval? The application keeps getting pushed back, and what was initially meant to be end 2015 back at the acquisition pushed back to third quarter 2016, and is now third/fourth quarter. As a conservative estimate, we’re looking at an approval before the end of the year.
As ever, we’re almost definitely going to see some level of dilution between now and a Fluticare commercialization push, purely to generate the capital required to execute on a marketing strategy. Cash is low, and revenues not nearly enough to fund operations post-approval. We think that this dilution can be offset by value-added if the company can snap up a small portion of the nasal spray market, however, and therein lies our bias.
Disclosure: We have NO position in INNV and have NOT been compensated for this article.
I'll take some .0001s ??
I doubt they would do anything even if they read it
Why buy shares premarket the way this thing has been trading lately?
Well the fact is the stock was promoted/pumped earlier. If you look at the charts it makes sense.
http://www.theotcinvestor.com/bayers-clarispray-success-bodes-well-for-innovus-pharmaceuticals-fluticare/
There was a disclaimer at the end of this article.
http://secfilings.com/disclaimer.aspx
Innovus Pharmaceuticals, Inc. (INNV)
Paid $1,000.00 in Cash on Jun 09, 2016 from Company
Paid $1,000.00 in Cash on Apr 27, 2016 from Company
That doesn't make the company a scam but it explains the short runs we've had.
I'm still holding shares
I think it likely we will see a drop before the approval to sell.
Drastic? I see -1.69% at the moment
I have a link to the pr but I wonder why I can't see it on etrade or ihub
I see that trade on Etrade
but the ghost town DJs have a hit called My Boo
See! You didn't see this coming. Wish I could load here.
My guess is stop loss trades have to be part of this
That might be because of the 1 million+ shares sold in the first minutes of trading
Thanks for sharing. Maybe a mod can sticky this or some of the other recent prs?
If it was obvious we would all be rich
sure if you have the right timing
I think we are losing our longs. I wonder if .105 is even a cheap price at this point.
I think other websites are just reposting it. Nothing new.
$INNV An Update On Innovus Pharmaceuticals Inc (OTCMKTS:INNV)
By Alex Carlson / in Biotech & Pharma, Momentum Stocks, Stocks / on Tuesday, 23 Aug 2016 05:10 AM
http://www.insiderfinancial.com/an-update-on-innovus-pharmaceuticals-inc-otcmktsinnv/116795/
Innovus Pharmaceuticals Inc (OTCMKTS:INNV) has been a favorite of ours at Insider Financial. With the closing of a $3m private placement and the company now cash flow positive, we believe things are just starting to heat up for shares of INNV. After establishing chart support earlier this month, INNV looks set to resume its bull run higher.
First up, a little background on the company. Innovus Pharma describes itself as an emerging leader in OTC and consumer products for men’s and women’s health and vitality. The company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
In the second quarter, the company turned cash flow positive with over $256,000 in cash provided by operations which is ahead of its projected timelines, due to higher revenues from the sale of its Beyond Human and Innovus Pharma products. Net revenues totaled over $1.0 million, $880,000 of which came from the sale of Beyond Human and Vesele® products. An increase of $836,000 as compared to net revenues of $183,000 for the same period in 2015. Gross profit on product sales was $757,000 or 74% of net revenues, compared to gross profit on product sales of $114,000 or 64% of net revenues, for the same period in 2015. The increase in gross profit on product sales was primarily due to sales from Beyond Human products.
Cash and cash equivalents were $198,000 as of June 30, 2016, an increase of $142,000 from $56,000 as of December 31, 2015. Innovus Pharma also had restricted cash of $1,305,000 as of June 30, 2016 which represents the cash proceeds from a convertible debt financing that was held in escrow until its release in July 2016. The cash does not include the additional $1,500,000 raised in July and approximately $200,000 received from exercise of Warrants. CEO Dr. Bassam Damaj said:
“Based on the huge success we are experiencing with our sales, we believe we are well positioned to achieve our projected $5M in revenues for 2016 without any revenue from our long awaited product FlutiCare™, currently under review by the FDA. To date we have exceeded our commercial expectations and with the projected launch of Sensum+®, RecalMax™ and Xyralid® in the second half of 2016 under the Beyond Human sales platform, we believe that revenues will continue to increase through the balance of 2016 and into 2017 and exceed our projections.”
While all of this is great news, what we’re waiting on is the pending FDA decision. The company has submitted an ANDA for its hay fever product, FlutiCare. The product is currently one of the top prescribed drugs in the indication in the US, but it’s not approved as an OTC, and that’s what Innovus is going for. This is a huge market currently dominated by GlaxoSmithKline plc (ADR) (NYSE:GSK) and its Flonase product, which became available OTC in February last year.
Even a small portion of the market would amount to tens of millions of dollars’ revenues, which is a big step up for Innovus Pharma. There’s also the fact that the OTC version will enjoy some residual brand recognition from the current prescription version, and so Innovus isn’t hitting markets cold – it’s got something of a running start. FlutiCare is the leading nasal steroid recommended by physicians for the treatment of nasal congestion, sneezing, runny nose, and itchy nose. FlutiCare Rx form has sold more than 177 million units, making it a clear leader in the Rx nasal steroid market.
The nasal steroid market is expected to become a $1+ billion market opportunity. With a 75% market share in the prescription market, FlutiCare is expected to become the clear leader in the OTC market given its efficacy and patient satisfaction if approved by the FDA. Considering the potential and INNV’s current market cap of just $37 million, INNV has the potential to be a multi-bagger if and when it gets FDA approval. We will be updating our subscribers as soon as we know more. For the latest updates on INNV, sign up below!
Disclosure: We have no position in INNV and have not been compensated for this article.
So we opening at .0001 tomorrow? What is the "new" company doing?
where are you getting the prescription?
He said fluticasone not fluticare
http://www.cvs.com/shop/brand-shop/c/cvs-fluticason/N-3qZcwciu5?DCSext.TriadCampID=89685
we are all speculating but if the company had investors waiting for financial filings wouldn't they move faster?
$INNV looks like Zacks made a good call
http://www.americanbankingnews.com/2016/08/17/zacks-investment-research-upgrades-innovus-pharmaceuticals-inc-innv-to-buy/
I've wondered for years if the SEC even pays attention to penny stocks
$INNV two green days not a bad way to end the week
Does the FDA usually announce in the morning or at any time throughout the day?